Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant?

被引:0
|
作者
Sheldon Preskorn
Steve Werder
机构
[1] University of Kansas School of Medicine-Wichita,Department of Psychiatry
来源
Neuropsychopharmacology | 2006年 / 31卷
关键词
antidepressants; drug–drug interactions; cytochrome ; 450 enzymes; serious adverse effects; polypharmacy;
D O I
暂无
中图分类号
学科分类号
摘要
This paper takes the position that detrimental drug–drug interactions (DDIs) involving antidepressants are clinically relevant. In doing so, it begins with a definition of the terms: drug–drug interaction, detrimental, and clinical relevance. It then discusses the issues of proof and provides an overview of the clinically relevant DDIs involving antidepressants. It also gives examples involving drugs besides antidepressants based on the premise that the underlying principles are applicable regardless of the therapeutic classes of the drugs involved.
引用
收藏
页码:1605 / 1612
页数:7
相关论文
共 50 条
  • [41] CLINICALLY RELEVANT ANTI-EPILEPTIC DRUG-INTERACTIONS
    PISANI, F
    PERUCCA, E
    DIPERRI, R
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1990, 18 (01) : 1 - 15
  • [42] Clinically relevant drug-drug and drug-food interactions: Underlying mechanisms and regulatory requirements for drug licensing
    Brewer L.
    Williams D.
    Pharmaceutical Medicine, 2013, 27 (1) : 9 - 23
  • [43] Characteristics of clinically relevant potential drug-drug interactions among ambulatory prescriptions in Slovenia
    Jazbar, Janja
    Gotar, Nina
    Locatelli, Igor
    Kos, Mitja
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (03) : 604 - 605
  • [44] No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin
    Derks, Michael
    Abt, Markus
    Parr, Graeme
    Meneses-Lorente, Georgina
    Young, Anne-Marie
    Phelan, Mary
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (10) : 1135 - 1145
  • [45] Mechanism of clinically relevant drug-drug interactions detected by a semi-automatic method
    Mora-Atorrasagasti, Oihana
    Lertxundi-Etxebarria, Unax
    Peral-Aguirregoitia, Javier
    Gabilondo-Zelaia, Itxasne
    Domingo-Echaburu, Saioa
    Jose Martinez-Bengoechea, Maria
    EJHP PRACTICE, 2008, 14 (05): : 32 - 36
  • [46] Letter to editor: Clinically relevant drug-drug interactions among elderly people with dementia
    Aranda-Salazar, Carmen
    Mendoza-Ramos, Jean
    Soto, Alonso
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1319 - 1319
  • [47] Letter to the Editor: Clinically relevant drug-drug interactions among elderly people with dementia
    Sonnerstam, Eva
    Sjolander, Maria
    Lovheim, Hugo
    Gustafsson, Maria
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1321 - 1322
  • [48] Phytochemical modulators of human drug metabolism: An introduction to clinically relevant herb-drug interactions
    Gurley, B. J.
    PLANTA MEDICA, 2014, 80 (10) : 755 - 755
  • [49] “Klinisch bedeutsame” neue Arzneimittelinteraktionen“Clinically relevant” new drug interactions
    Uwe Fuhr
    Medizinische Klinik, 1999, 94 (2) : 120 - 124
  • [50] DGIdb 2.0: mining clinically relevant drug-gene interactions
    Wagner, Alex H.
    Coffman, Adam C.
    Ainscough, Benjamin J.
    Spies, Nicholas C.
    Skidmore, Zachary L.
    Campbell, Katie M.
    Krysiak, Kilannin
    Pan, Deng
    McMichael, Joshua F.
    Eldred, James M.
    Walker, Jason R.
    Wilson, Richard K.
    Mardis, Elaine R.
    Griffith, Malachi
    Griffith, Obi L.
    NUCLEIC ACIDS RESEARCH, 2016, 44 (D1) : D1036 - D1044